Pr VERGES Bruno
Fiche personne
coordonnées
Hôpital François Mitterrand
14 rue Gaffarel
21079 DIJON Cedex
+33 3 80 29 32 54
Territoire
Bourgogne
Statut
Hospitalo-Universitaire
équipes/plateformes
Equipe UMR 1231 - Equipe "Physiopathologie des dyslipidémies (PADYS)"
Recherche
Expertises :
- Recherche:Biologie Cellulaire
- Recherche:Biologie Moléculaire
Publications
Hypertriglyceridemia Results From an Impaired Catabolism of Triglyceride-Rich Lipoproteins in -Related Lipodystrophy.
Vergès B, Vantyghem MC, Reznik Y, Duvillard L, Rouland A, Capel E, Vigouroux C
Arterioscler Thromb Vasc Biol. 2024 06 20;:
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès B
Ann Endocrinol (Paris). 2024 05 31;:
Heterogeneity of glycaemic phenotypes in type 1 diabetes.
Fagherazzi G, Aguayo GA, Zhang L, Hanaire H, Picard S, Sablone L, Vergès B, Hamamouche N, Detournay B, Joubert M, Delemer B, Guilhem I, Vambergue A, Gourdy P, Hadjadj S, Velayoudom FL, Guerci B, Larger E, Jeandidier N, Gautier JF, Renard E, Potier L, Benhamou PY, Sola A, Bordier L, Bismuth E, Prévost G, Kessler L, Cosson E, Riveline JP,
Diabetologia. 2024 05 23;:
Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes.
Denimal D, Duvillard L, Béland-Bonenfant S, Terriat B, Pais-de-Barros JP, Simoneau I, Rouland A, Houbachi L, Bouillet B, Vergès B, Petit JM
Diabetes Metab. 2024 05 4;:101542
No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
Duvillard L, de Barros JP, Rouland A, Simoneau I, Denimal D, Bouillet B, Petit JM, Vergès B
Diabetes Metab. 2024 04 21;:101535
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.
Störmann S, Meyhöfer SM, Groener JB, Faust J, Schilbach K, Seufert J, Vergès B
Front Endocrinol (Lausanne). 2024 02 9;15:1348990
Tobacco smoking and diabetes. A comparative survey among diabetologists and smoking cessation specialists.
Berlin I, Durlach V, Thomas D, Vergès B, Le Faou AL,
Prim Care Diabetes. 2024 01 30;:
Screening and management of metabolic complications of mTOR inhibitors in real-life settings.
Spanjaard P, Petit JM, Schmitt A, Vergès B, Bouillet B
Ann Endocrinol (Paris). 2023 12 1;:
Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes.
Denimal D, Béland-Bonenfant S, Pais-de-Barros JP, Rouland A, Bouillet B, Duvillard L, Vergès B, Petit JM
Cardiovasc Diabetol. 2023 11 8;22(1):310
Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP).
Brue T, Rahabi H, Barry A, Barlier A, Bertherat J, Borson-Chazot F, Castinetti F, Cazabat L, Chabre O, Chevalier N, Christin-Maitre S, Cortet C, Drui D, Kamenicky P, Lançon C, Lioté F, Pellegrini I, Reynaud R, Salenave S, Tauveron I, Touraine P, Vantyghem MC, Vergès B, Vezzosi D, Villa C, Raverot G, Coutant R, Chanson P, Albarel F
Ann Endocrinol (Paris). 2023 08 12;:
Cardiovascular disease in type 1 diabetes, an underestimated danger: Epidemiological and pathophysiological data.
Vergès B
Atherosclerosis. 2023 06 20;:
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.
Denimal D, Bergas V, Pais-de-Barros JP, Simoneau I, Demizieux L, Passilly-Degrace P, Bouillet B, Petit JM, Rouland A, Bataille A, Duvillard L, Vergès B
Cardiovasc Diabetol. 2023 05 4;22(1):104
Early Retinal Microvascular Changes Assessed with Swept-Source OCT Angiography in Type 1 Diabetes Patients without Retinopathy.
Eid P, Creuzot-Garcher C, Aho LS, Gabrielle PH, Charpin E, Haddad D, Steinberg LA, Bron A, Verges B, Arnould L
J Clin Med. 2023 04 4;12(7):
Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy.
Jacquot L, Pointeau O, Roger-Villeboeuf C, Passilly-Degrace P, Belkaid R, Regazzoni I, Leemput J, Buch C, Demizieux L, Vergès B, Degrace P, Crater G, Jourdan T
Front Nephrol. 2023 03 28;3:1138416
Diabetes Induced by Immune Checkpoint Inhibitors (ICIs).
Vergès B
Ann Endocrinol (Paris). 2023 03 23;:
Prevalence of sleep apnea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: a French nationwide prospective study.
Pépin JL, Bailly S, Texereau JB, Sonnet E, Picard S, Vergès B, Coffin Boutreux C, Arnault Ouary G, Kessler L, Guerci B, Anton Kuchly B, Fendri Gaied S, Cuperlier A, Voinot C, Derrien C, Dubois S, Lavergne F, Borel AL, Tamisier R, Benhamou PY
Diabetes Obes Metab. 2023 02 15;:
Concise review of lipidomics in nonalcoholic fatty liver disease.
Béland-Bonenfant S, Rouland A, Petit JM, Vergès B
Diabetes Metab. 2023 02 11;:101432
High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity.
Denimal D, Monier S, Bouillet B, Vergès B, Duvillard L
Metabolites. 2023 02 9;13(2):
Smoking and diabetes: sex and gender aspects and their impact on vascular diseases.
Tramunt B, Rouland A, Durlach V, Vergès B, Thomas D, Berlin I, Clair C
Can J Cardiol. 2023 01 23;:
Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review.
Rouland A, Masson D, Lagrost L, Vergès B, Gautier T, Bouillet B
Cardiovasc Diabetol. 2022 12 5;21(1):272
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.
Vergès B, Aboyans V, Angoulvant D, Boutouyrie P, Cariou B, Hyafil F, Mohammedi K, Amarenco P
Cardiovasc Diabetol. 2022 11 15;21(1):242
Hospitalizations for Anorexia Nervosa during the COVID-19 Pandemic in France: A Nationwide Population-Based Study.
Chauvet-Gelinier JC, Roussot A, Vergès B, Petit JM, Jollant F, Quantin C
J Clin Med. 2022 08 16;11(16):
HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.
Denimal D, Monier S, Simoneau I, Duvillard L, Vergès B, Bouillet B
Cardiovasc Diabetol. 2022 08 12;21(1):154
Smoking and diabetes interplay: A comprehensive review and joint statement.
Durlach V, Vergès B, Al-Salameh A, Bahougne T, Benzerouk F, Berlin I, Clair C, Mansourati J, Rouland A, Thomas D, Thuillier P, Tramunt B, Faou AL
Diabetes Metab. 2022 06 29;:101370
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H, Vantyghem MC, Nobécourt E, Andreelli F, Archambeaud F, Bismuth E, Briet C, Cartigny M, Chevalier B, Donadille B, Daguenel A, Fichet M, Gautier JF, Janmaat S, Jéru I, Legagneur C, Leguier L, Maitre J, Mongeois E, Poitou C, Renard E, Reznik Y, Spiteri A, Travert F, Vergès B, Zammouri J, Vigouroux C, Vatier C
Diabetes Obes Metab. 2022 Apr 20;:
Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).
Mosbah H, Donadille B, Vatier C, Janmaat S, Atlan M, Badens C, Barat P, Béliard S, Beltrand J, Ben Yaou R, Bismuth E, Boccara F, Cariou B, Chaouat M, Charriot G, Christin-Maitre S, De Kerdanet M, Delemer B, Disse E, Dubois N, Eymard B, Fève B, Lascols O, Mathurin P, Nobécourt E, Poujol-Robert A, Prevost G, Richard P, Sellam J, Tauveron I, Treboz D, Vergès B, Vermot-Desroches V, Wahbi K, Jéru I, Vantyghem MC, Vigouroux C
Orphanet J Rare Dis. 2022 Apr 19;17(Suppl 1):170
Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist.
Muller T, Demizieux L, Troy-Fioramonti S, Buch C, Leemput J, Belloir C, Pais de Barros JP, Jourdan T, Passilly-Degrace P, Fioramonti X, Le Bon AM, Vergès B, Robert JM, Degrace P
Int J Mol Sci. 2022 Mar 8;23(6):
Healing of diabetic foot ulcers is independently associated with the use of angiotensin receptor blockers but not with those of diuretics and angiotensin conversion enzyme inhibitors.
Lapray M, Petit JM, Fourmont C, Rouland A, Vergès B, Bouillet B
Diabetes Metab. 2022 Mar 1;:101336
Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk.
Masson W, Barbagelata L, Lavalle-Cobo A, Lobo M, Masson G, Nogueira JP, Vergès B
Diabetes Metab Syndr. 2022 Jan 8;16(1):102391
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: the SFDT1 study.
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E
Diabetes Metab. 2021 Nov 21;:101306
Pituitary adenoma in patients with multiple endocrine neoplasia type 1 - a cohort study.
Le Bras M, Leclerc H, Rousseau O, Goudet P, Cuny T, Castinetti F, Bauters C, Chanson P, Tabarin A, Gaujoux S, Christin-Maitre S, Ruszniewski P, Borson-Chazot F, Guilhem I, Caron P, Goichot B, Beckers A, Delemer B, Raingeard I, Vergès B, Smati S, Wargny M, Cariou B, Hadjadj S
Eur J Endocrinol. 2021 Oct 1;:
History of bariatric surgery and COVID 19 outcomes in patients with type 2 diabetes: results from the CORONADO study.
Blanchard C, Perennec T, Smati S, Tramunt B, Guyomarch B, Bigot-Corbel E, Bordier L, Borot S, Bourron O, Caussy C, Coffin-Boutreux C, Dutour A, Germain N, Gonfroy-Leymarie C, Meyer L, Prevost G, Roussel R, Seret-Bégué D, Thivolet C, Vergès B, Pichelin M, Gourdy P, Hadjadj S, Wargny M, Pattou F, Cariou B,
Obesity (Silver Spring). 2021 Sep 29;:
Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.
Vergès B, Hassid J, Rouland A, Bouillet B, Simoneau I, Petit JM, Duvillard L
Diabetes Metab. 2021 Sep 19;:101284
Management of diabetes mellitus in patients with cirrhosis: an overview and joint statement.
Boursier J, Anty R, Carette C, Cariou B, Castera L, Caussy C, Fontaine H, Garioud A, Gourdy P, Guerci B, Guillaume M, Michot N, Minello A, Ouizeman DJ, Serfaty L, Bonnet F, Vergès B, Petit JM,
Diabetes Metab. 2021 Aug 4;:101272
Frequent and severe hypoglycaemia detected with continuous glucose monitoring in older institutionalised patients with diabetes.
Bouillet B, Tscherter P, Vaillard L, Nonciaux C, Hourdain P, Ravier A, Rouland A, Petit JM, Vergès B, Quilot E
Age Ageing. 2021 Jul 27;:
Impact of the COVID-19 Epidemic on hospitalization for diabetic foot ulcers during lockdown: A French nationwide population-based study.
Mariet AS, Benzenine E, Bouillet B, Vergès B, Quantin C, Petit JM
Diabet Med. 2021 Apr 2;:e14577
Fewer Type A personality traits in type 2 diabetes patients with diabetic foot ulcer.
Vergès B, Brands R, Fourmont C, Petit JM, Simoneau I, Rouland A, Legris P, Bouillet B, Chauvet-Gélinier JC
Diabetes Metab. 2021 Mar 12;:101245
Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.
Wargny M, Potier L, Gourdy P, Pichelin M, Amadou C, Benhamou PY, Bonnet JB, Bordier L, Bourron O, Chaumeil C, Chevalier N, Darmon P, Delenne B, Demarsy D, Dumas M, Dupuy O, Flaus-Furmaniuk A, Gautier JF, Guedj AM, Jeandidier N, Larger E, Le Berre JP, Lungo M, Montanier N, Moulin P, Plat F, Rigalleau V, Robert R, Seret-Bégué D, Sérusclat P, Smati S, Thébaut JF, Tramunt B, Vatier C, Velayoudom FL, Vergès B, Winiszewski P, Zabulon A, Gourraud PA, Roussel R, Cariou B, Hadjadj S,
Diabetologia. 2021 Feb 17;:
Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability?
Vergès B, Pignol E, Rouland A, Bouillet B, Baillot-Rudoni S, Quilot E, Djeffal A, Petit JM
J Diabetes Sci Technol. 2021 Feb 10;:1932296821992060
Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Petit JM, Degrace P, Demizieux L
Diabetes Care. 2021 Feb 2;:
Diabetes is not associated with COVID-19-related mortality in older institutionalized people.
Legris P, Vaillard L, Nonciaux C, Hourdain P, Taroux M, Petit JM, Vergès B, Bouillet B
Diabetes Metab. 2021 Jan 27;:101235
Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human.
Buch C, Muller T, Leemput J, Passilly-Degrace P, Ortega-Deballon P, Pais de Barros JP, Vergès B, Jourdan T, Demizieux L, Degrace P
Front Endocrinol (Lausanne). 2021 ;12:716431
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion.
Rouland A, Bouillet B, Legris P, Simoneau I, Petit JM, Vergès B
Clin Pharmacol. 2021 ;13:33-37
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology.
Valensi P, Henry P, Boccara F, Cosson E, Prevost G, Emmerich J, Ernande L, Marcadet D, Mousseaux E, Rouzet F, Sultan A, Ferrières J, Vergès B, Van Belle E
Arch Cardiovasc Dis. 2020 Dec 9;:
Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: results from the CORONADO study.
Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vatier C, Vergès B, Ancelle D, Amadou C, Bachir LA, Bourron O, Coffin-Boutreux C, Barraud S, Dorange A, Fremy B, Gautier JF, Germain N, Larger E, Laugier-Robiolle S, Meyer L, Monier A, Moura I, Potier L, Sabbah N, Seret-Bégué D, Winiszewski P, Pichelin M, Saulnier PJ, Hadjadj S, Cariou B, Gourdy P,
Diabetes Obes Metab. 2020 Oct 14;:
Cardiovascular disease with type 1 diabetes: A review of epidemiological data and underlying mechanisms.
Vergès B
Diabetes Metab.. 2020 Sep 27;:
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus.
Valensi P, Belle EV, Cosson E, Emmerich J, Prevost G, Ferriere J, Sultan A, Ernande L, Rouzet F, Marcadet D, Mousseau E, Boccara F, Verges B, Henry P
Diabetes Metab.. 2020 Aug 23;:
Increased body fat mass reduces the association between fructosamine and HbA1c in obese type 2 diabetic patients.
Vergès B, Rouland A, Baillot-Rudoni S, Brindisi MC, Duvillard L, Simoneau I, Legris P, Petit JM, Bouillet B
J Diabetes Investig. 2020 Aug 7;:
Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.
Roger C, Buch C, Muller T, Leemput J, Demizieux L, Passilly-Degrace P, Cinar R, Iyer MR, Kunos G, Vergès B, Degrace P, Jourdan T
Diabetes. 2020 Jul 17;:
Identification of an oral microbiota signature associated with an impaired orosensory perception of lipids in insulin-resistant patients.
Besnard P, Christensen JE, Bernard A, Simoneau-Robin I, Collet X, Verges B, Burcelin R
Acta Diabetol. 2020 Jul 16;:
Association between hospital admission for ketoacidosis and subsequent suicide attempt in young adults with type 1 diabetes.
Petit JM, Goueslard K, Chauvet-Gelinier JC, Bouillet B, Vergès B, Jollant F, Quantin C
Diabetologia. 2020 Jul 8;:
Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration - a proof of concept.
Bouillet B, Gautier T, Denimal D, Samson M, Masson D, Pais de Barros JP, Maquart G, Xolin M, Grosfeld A, Dalle H, Vergès B, Moldes M, Fève B
Eur. J. Endocrinol.. 2020 Jun 1;:
Are older patients with diabetes still being overtreated in French long-term care homes?
Quilot E, Petit JM, Vergès B, Bouillet B
Age Ageing. 2020 May 26;:
Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene.
Bouillet B, Crevisy E, Baillot-Rudoni S, Gallegarine D, Jouan T, Duffourd Y, Petit JM, Vergès B, Callier P
Diabetes Metab.. 2020 Mar 14;:
[Thyroiditis: What's new in 2019?]
Rouland A, Buffier P, Petit JM, Vergès B, Bouillet B
Rev Med Interne. 2020 Feb 24;:
Personality types in individuals with type 1 and type 2 diabetes.
Rouland A, Chauvet-Gelinier JC, Sberna AL, Crevisy E, Buffier P, Mouillot T, Petit JM, Verges B
Endocr Connect. 2020 Feb 1;:
[Who is at risk for drug-drug interactions in type 2 diabetic patients?]
Laurent C, Aho Glele LS, Lazzarotti A, Petit JM, Vergès B, Bouillet B
Presse Med. 2019 Nov 21;:
Physical and Psychological Effectiveness of Cardiac Rehabilitation: Age Is Not a Limiting Factor!
Deley G, Culas C, Blonde MC, Mourey F, Vergès B
Can J Cardiol. 2019 Oct;35(10):1353-1358
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M
Diabetes Metab.. 2019 Sep 10;:
Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.
Fritzen K, Basinska K, Stautner C, Braun KF, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Hosny Y, Schnell O
J Diabetes Sci Technol. 2019 Aug 6;:1932296819864665
A low-carbohydrate high-fat diet initiated promptly after diagnosis provides clinical remission in three patients with type 1 diabetes.
Bouillet B, Rouland A, Petit JM, Vergès B
Diabetes Metab.. 2019 Jul 10;:
Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration but not with visceral fat and liver fat content in people with type 1 diabetes.
Bouillet B, Gautier T, Rouland A, Duvillard L, Petit JM, Lagrost L, Vergès B
Acta Diabetol. 2019 May 22;:
Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.
Michiels Y, Bugnon O, Chicoye A, Dejager S, Moisan C, Allaert FA, Hunault C, Romengas L, Méchin H, Vergès B
Adv Ther. 2019 May 2;:
CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes.
Bouillet B, Gautier T, Terriat B, Lagrost L, Verges B, Petit JM
Acta Diabetol. 2019 Apr 12;:
Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.
Fritzen K, Basinska K, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Zakrzewska K, Schnell O
J Diabetes Sci Technol. 2019 Mar 27;:1932296819835172
Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction.
Benalia M, Zeller M, Mouhat B, Guenancia C, Yameogo V, Greco C, Yao H, Maza M, Vergès B, Cottin Y
Diabetes Metab.. 2019 Feb 11;:
Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.
Guerci B, Charbonnel B, Gourdy P, Hadjadj S, Hanaire H, Marre M, Vergès B
Diabetes Metab.. 2019 Jan 21;:
Depression and obesity, data from a national administrative database study: Geographic evidence for an epidemiological overlap.
Chauvet-Gelinier JC, Roussot A, Cottenet J, Brindisi MC, Petit JM, Bonin B, Vergès B, Quantin C
PLoS ONE. 2019 ;14(1):e0210507
Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes.
Chauvet-Gélinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebaï A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Vergès B
Diabetes Metab.. 2018 Nov 23;:
Malnutrition in type 2 diabetic patients does not affect healing of foot ulcers.
Rouland A, Fourmont C, Sberna AL, Aho Glele LS, Mouillot T, Simoneau I, Vergès B, Petit JM, Bouillet B
Acta Diabetol. 2018 Oct 3;:
French Endocrine Society Guidance on endocrine side-effects of immunotherapy.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Endocr. Relat. Cancer. 2018 Oct 1;:
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Wargny M, Ducluzeau PH, Petit JM, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B
Atherosclerosis. 2018 Sep 13;278:82-90
[Is reduction of hyperglycemia associated with a cardiovascular benefit?]
Vergès B
Presse Med. 2018 Sep 12;:
Expert opinion on the metabolic complications of mTOR inhibitors.
Bouillet B, Buffier P, Smati S, Archambeaud F, Cariou B, Vergès B
Ann. Endocrinol. (Paris). 2018 Aug 22;:
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.
Buffier P, Bouillet B, Smati S, Archambeaud F, Cariou B, Verges B
Ann. Endocrinol. (Paris). 2018 Aug 1;:
Expert opinion on immunotherapy induced diabetes.
Smati S, Buffier P, Bouillet B, Archambeaud F, Vergès B, Cariou B
Ann. Endocrinol. (Paris). 2018 Jul 25;:
Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.
Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Sberna AL, Petit JM, Degrace P, Demizieux L
Arterioscler. Thromb. Vasc. Biol.. 2018 Jul 19;:
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Ann. Endocrinol. (Paris). 2018 Jul 11;:
New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia.
Serveaux Dancer M, Di Filippo M, Marmontel O, Valéro R, Piombo Rivarola MDC, Peretti N, Caussy C, Krempf M, Vergès B, Mahl M, Marçais C, Moulin P, Charrière S
J Clin Lipidol. 2018 Jul 7;:
Author Correction: Obese Subjects With Specific Gustatory Papillae Microbiota and Salivary Cues Display an Impairment to Sense Lipids.
Besnard P, Christensen JE, Brignot H, Bernard A, Passilly-Degrace P, Nicklaus S, Pais de Barros JP, Collet X, Lelouvier B, Servant F, Blasco-Baque V, Verges B, Lagrost L, Feron G, Burcelin R
Sci Rep. 2018 Jun 22;8(1):9773
Obese Subjects With Specific Gustatory Papillae Microbiota and Salivary Cues Display an Impairment to Sense Lipids.
Besnard P, Christensen JE, Brignot H, Bernard A, Passilly-Degrace P, Nicklaus S, Pais de Barros JP, Collet X, Lelouvier B, Servant F, Blasco V, Verges B, Lagrost L, Feron G, Burcelin R
Sci Rep. 2018 Apr 30;8(1):6742
Unexpected adverse effect of metyrapone: a case report.
Rouland A, Nguyen A, Fourmont C, Lapray M, Vergès B, Petit JM, Bouillet B
Clin. Endocrinol. (Oxf). 2018 Apr 19;:
Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels.
Nguyen A, Ricolfi F, Lemogne B, Aho S, Lemaire S, Bouillet B, Duvillard L, Denimal D, Fourmont C, Loffroy R, Cercueil JP, Verges B, Petit JM
Horm. Metab. Res.. 2018 Apr;50(4):303-307
Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes.
Petit JM, Bouillet B, Loffroy R, Rouland A, Hillon P, Verges B
J. Hepatol.. 2018 Mar;68(3):603-604
Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: Is glycated haemoglobin useful? Data from the prospective REHABDIAB study.
Tatulashvili S, Patois-Vergès B, Nguyen A, Blonde MC, Vergès B
Eur J Prev Cardiol. 2018 Mar;25(5):464-471
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver diseas
Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Vergès B, Hillon P, Petit JM
Diabet. Med.. 2018 Mar;35(3):368-375
Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.
Lecomte P, Binquet C, Le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F, Lombard-Bohas C, Baudin E, Delemer B, Klein M, Vergès B, Aparicio T, Cosson E, Beckers A, Caron P, Chabre O, Chanson P, Du Boullay H, Guilhem I, Niccoli P, Rohmer V, Guigay J, Vulpoi C, Scoazec JY, Goudet P
World J Surg. 2017 Aug;:
Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
Ait Boudaoud A, Verges B, Petit JM, Tatulashvili S, Cochet A, Humbert O
Nucl Med Commun. 2017 Jul;:
High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study.
Vergès B, Patois-Vergès B, Goueslard K, Cottenet J, Nguyen A, Tatulashvili S, Blonde MC, Quantin C
Diabetes Metab.. 2017 Jun;:
After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
Vergès B, Charbonnel B
Diabetes Metab.. 2017 Apr;43 Suppl 1:2S3-2S12
Type A personality is not associated with poor glycaemic control: Data from cross-sectional and longitudinal surveys of people with type 1 or type 2 diabetes.
Chauvet-Gélinier JC, Trojak B, Lemogne C, Louprou A, Bouillet B, Simoneau I, Chahraoui K, Petit JM, Consoli SM, Bonin B, Vergès B
Diabetes Metab.. 2017 Apr;43(2):176-179
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
Laugier-Robiolle S, Vergès B, Le Bras M, Gand E, Bouillet B, Saulnier PJ, Le May C, Pichelin M, Maréchaud R, Petit JM, Hadjadj S, Cariou B
Diabetes Obes Metab. 2017 Mar;19(3):448-451
Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.
Denimal D, Monier S, Brindisi MC, Petit JM, Bouillet B, Nguyen A, Demizieux L, Simoneau I, Pais de Barros JP, Vergès B, Duvillard L
Arterioscler. Thromb. Vasc. Biol.. 2017 Mar;:
Overactivation of the endocannabinoid system alters the anti-lipolytic action of insulin in mouse adipose tissue.
Muller T, Demizieux L, Troy-Fioramonti S, Gresti J, Pais de Barros JP, Berger H, Vergès B, Degrace P
Am. J. Physiol. Endocrinol. Metab.. 2017 Mar;:ajpendo.00374.2016
Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD.
Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Söderlund S, Ståhlman M, Adiels M, Hakkarainen A, Lundbom N, Kilicarslan M, Hallström BM, Lundbom J, Vergès B, Barrett PH, Watts GF, Serlie MJ, Nielsen J, Uhlén M, Smith U, Marschall HU, Taskinen MR, Boren J
Mol. Syst. Biol.. 2017 Mar;13(3):916
Consensus statement on the management of dyslipidaemias in adults.
, , , Béliard S, Bonnet F, Bouhanick B, Bruckert E, Cariou B, Charrière S, Durlach V, Moulin P, Valéro R, Vergès B
Ann. Endocrinol. (Paris). 2017 Feb;78(1):43-53
Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B
J. Clin. Endocrinol. Metab.. 2017 Feb;102(2):407-415
Effects of Transcranial Magnetic Stimulation on the Hypothalamic-Pituitary Axis in Depression: Results of a Pilot Study.
Meille V, Verges B, Lalanne L, Jonval L, Duvillard L, Chavet-Gelinier JC, Bonin B, Trojak B
J Neuropsychiatry Clin Neurosci. 2017 ;29(1):70-73
Consensus statement on the management of dyslipidaemias in adults.
, , , Béliard S, Bonnet F, Bouhanick B, Bruckert E, Cariou B, Charrière S, Durlach V, Moulin P, Valéro R, Vergès B
Diabetes Metab.. 2016 Dec;42(6):398-408
Fatty acid dietary intake in the general French population: are the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) national recommendations met?
Tressou J, Moulin P, Vergès B, Le Guillou C, Simon N, Pasteau S
Br. J. Nutr.. 2016 Dec;116(11):1966-1973
Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study.
Balkau B, Halimi S, Blickle JF, Vergès B, Avignon A, Attali C, Chartier I, Amelineau E
Ann. Endocrinol. (Paris). 2016 Dec;77(6):649-657
Adrenal lymphoma: presentation, management and prognosis.
Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM
QJM. 2016 Oct;:
[Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome].
Vergès B
Presse Med. 2016 Oct;45(10):865-870
Béliard S, Bonnet F, Bouhanick B, Charrière S, Cariou B, Durlach V, Moulin P, Valéro R, Vergès B, Boccara F, Farnier M, Feve B, Gourdy P, Guerci B, Krempf M, Moulin P
Rev Prat. 2016 Sep;66(7):727-728
Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration, but not visceral fat, in patients with type 2 diabetes.
Bouillet B, Gautier T, Aho LS, Duvillard L, Petit JM, Lagrost L, Vergès B
Diabetes Metab.. 2016 Sep;42(4):263-6
ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.
Vergès B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Söderlund S, Matikainen N, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Aho S, Simoneau-Robin I, Taskinen MR
J. Clin. Endocrinol. Metab.. 2016 Apr;101(4):1398-406
Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes.
Chauvet-Gélinier JC, Trojak B, Lemogne C, Aho-Glélé LS, Brindisi MC, Bouillet B, Ponavoy E, Meille V, Simoneau I, Chahraoui K, Vaillant G, Petit JM, Consoli SM, Bonin B, Vergès B
Diabetes Metab.. 2016 Apr;42(2):88-95
Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome.
Denimal D, Nguyen A, Pais de Barros JP, Bouillet B, Petit JM, Vergès B, Duvillard L
Atherosclerosis. 2016 Mar;246:106-14
Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis.
Vergès B, Petit JM, Bouillet B
Diabetes Metab.. 2016 Feb;42(1):1-3
Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients.
Loffroy R, Terriat B, Jooste V, Robin I, Brindisi MC, Hillon P, Vergès B, Cercueil JP, Petit JM
Quant Imaging Med Surg. 2015 Dec;5(6):792-8
Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation.
Perségol L, Brindisi MC, Rageot D, Pais de Barros JP, Monier S, Vergès B, Duvillard L
Heart Vessels. 2015 Nov;30(6):845-9
Unravelling the intra-familial correlations and heritability of tumor types in MEN1, a GTE study.
Thevenon J, Bourredjem A, Faivre L, Bauters C, Calender A, Lebras M, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Pasmant E, Chabre O, Castermans E, Ruszniewski P, Bertherat J, Delemer B, Christin-Maitre S, Beckers A, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Schillo F, Bihan H, Archambeaud F, Kerlan V, Bourcigaux N, Kuhn JM, Verges B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P
Eur J Endocrinol. 2015 Sep 21. pii: EJE-15-0691.
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study.
Boren J, Watts GF, Adiels M, Soderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Verges B, Barrett PH, Taskinen MR
Arterioscler Thromb Vasc Biol. 2015 Aug 27. pii: ATVBAHA.115.305614.
Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study.
Vergès B, Patois-Vergès B, Iliou MC, Simoneau-Robin I, Bertrand JH, Feige JM, Douard H, Catargi B, Fischbach M,
BMC Cardiovasc Disord. 2015 Jul;15:64
Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration.
Denimal D, Pais de Barros JP, Petit JM, Bouillet B, Verges B, Duvillard L
Atherosclerosis. 2015 Jun 29;241(2):752-760
GCKR polymorphism influences liver fat content in patients with type 2 diabetes.
Petit JM, Masson D, Guiu B, Rollot F, Duvillard L, Bouillet B, Brindisi MC, Buffier P, Hillon P, Cercueil JP, Verges B
Acta Diabetol. 2015 May 16.
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès B
Diabetologia. 2015 May;58(5):886-99
Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis.
Petit JM, Pedro L, Guiu B, Duvillard L, Bouillet B, Jooste V, Habchi M, Crevisy E, Fourmont C, Buffier P, Hillon P, Cercueil JP, Verges B
Diabet Med. 2015 May 16
MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'etude des Tumeurs Endocrines.
Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Levy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Verges B, Sadoul JL, Menegaux F, Tabarin A, Kuhn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B
J Clin Endocrinol Metab. 2015 Apr;100(4):1568-77
Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice.
Troy-Fioramonti S, Demizieux L, Gresti J, Muller T, Verges B, Degrace P
Diabetes. 2015 Mar;64(3):808-18
Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes.
Blache D, Bourdon E, Salloignon P, Lucchi G, Ducoroy P, Petit JM, Verges B, Lagrost L
Diabetes. 2015 Mar;64(3):960-72
Potential risks associated with increased plasma plant-sterol levels.
Verges B, Fumeron F
Diabetes Metab. 2015 Feb;41(1):76-81
Adverse effects and safety of SGLT-2 inhibitors.
Halimi S, Verges B
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S28-34
Circulating apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control.
Habchi M, Duvillard L, Cottet V, Brindisi MC, Bouillet B, Beacco M, Crevisy E, Buffier P, Baillot-Rudoni S, Verges B, Petit JM
Clin Endocrinol (Oxf). 2014 Nov;81(5):696-701
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Persegol L, Duvillard L, Monier S, Brindisi MC, Bouillet B, Petit JM, Verges B
J Clin Endocrinol Metab. 2014 Oct;99(10):E2015-9
Changes in lipoprotein kinetics associated with type 2 diabetes affect the distribution of lipopolysaccharides among lipoproteins.
Verges B, Duvillard L, Lagrost L, Vachoux C, Garret C, Bouyer K, Courtney M, Pomie C, Burcelin R
J Clin Endocrinol Metab. 2014 Jul;99(7):E1245-53
The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.
Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton AM, Harno K, Satman I, Verges B
J Diabetes Sci Technol. 2014 Jul;8(4):783-90
Characteristics of diabetic patients and diabetes care in cardiac rehabilitation.
Beacco M, Verges-Patois B, Blonde MC, Crevisy E, Habchi M, Bouillet B, Buffier P, Petit JM, Verges B
Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):391-7
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.
Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceska R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglu L, Toth PP, Valensi P, Verges B
Atheroscler Suppl. 2014 Jun;15(1):1-15
Obesity interferes with the orosensory detection of long-chain fatty acids in humans.
Chevrot M, Passilly-Degrace P, Ancel D, Bernard A, Enderli G, Gomes M, Robin I, Issanchou S, Verges B, Nicklaus S, Besnard P
Am J Clin Nutr. 2014 May;99(5):975-83
Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism.
Verges B, Walter T, Cariou B
Eur J Endocrinol. 2014 Feb 1;170(2):R43-55
[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C, Cariou B, Verges B, Coriat R, N'guyen T, Francois E, Hammel P, Niccoli P, Hentic O
Bull Cancer. 2014 Feb;101(2):175-83
3q27.3 microdeletional syndrome: a recognisable clinical entity associating dysmorphic features, marfanoid habitus, intellectual disability and psychosis with mood disorder.
Thevenon J, Callier P, Poquet H, Bache I, Menten B, Malan V, Cavaliere ML, Girod JP, Thauvin-Robinet C, El Chehadeh S, Pinoit JM, Huet F, Verges B, Petit JM, Mosca-Boidron AL, Marle N, Mugneret F, Masurel-Paulet A, Novelli A, Tumer Z, Loeys B, Lyonnet S, Faivre L
J Med Genet. 2014 Jan;51(1):21-7
Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation.
Brindisi MC, Duvillard L, Monier S, Verges B, Persegol L
Diabetes Metab Res Rev. 2013 Nov;29(8):618-23
Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.
Thevenon J, Bourredjem A, Faivre L, Cardot-Bauters C, Calender A, Murat A, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Parfait B, Chabre O, Castermans E, Beckers A, Ruszniewski P, Le Bras M, Delemer B, Bouchard P, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Penfornis A, Bihan H, Archambeaud F, Kerlan V, Duron F, Kuhn JM, Verges B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P
Hum Mol Genet. 2013 May 15;22(10):1940-8
Physical activity and type 2 diabetes. Recommandations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group.
Duclos M, Oppert JM, Verges B, Coliche V, Gautier JF, Guezennec Y, Reach G, Strauch G
Diabetes Metab. 2013 May;39(3):205-16
Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verges B
Diabetes Metab. 2013 Feb;39(1):34-41
Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional study.
Grandfils N, Detournay B, Attali C, Joly D, Simon D, Verges B, Toussi M, Briand Y, Delaitre O
Int J Endocrinol. 2013;2013:640632
Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus.
Verges B, Guiu B, Cercueil JP, Duvillard L, Robin I, Buffier P, Bouillet B, Aho S, Brindisi MC, Petit JM
Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):3050-7
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.
Gourdy P, Bachelot A, Catteau-Jonard S, Chabbert-Buffet N, Christin-Maitre S, Conard J, Fredenrich A, Gompel A, Lamiche-Lorenzini F, Moreau C, Plu-Bureau G, Vambergue A, Verges B, Kerlan V
Ann Endocrinol (Paris). 2012 Nov;73(5):469-87
Diabetes as a case study of chronic disease management with a personalized approach: the role of a structured feedback loop.
Ceriello A, Barkai L, Christiansen JS, Czupryniak L, Gomis R, Harno K, Kulzer B, Ludvigsson J, Nemethyova Z, Owens D, Schnell O, Tankova T, Taskinen MR, Verges B, Weitgasser R, Wens J
Diabetes Res Clin Pract. 2012 Oct;98(1):5-10
Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes.
Brindisi MC, Guiu B, Duvillard L, Athias A, Rollot F, Bouillet B, Beacco M, Hillon P, Cercueil JP, Verges B, Petit JM
Atherosclerosis. 2012 Oct;224(2):465-8
Prognosis in 41 severely malnourished anorexia nervosa patients.
Rigaud D, Tallonneau I, Brindisi MC, Verges B
Clin Nutr. 2012 Oct;31(5):693-8
Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes.
Petit JM, Guiu B, Duvillard L, Jooste V, Brindisi MC, Athias A, Bouillet B, Habchi M, Cottet V, Gambert P, Hillon P, Cercueil JP, Verges B
Clin Nutr. 2012 Aug;31(4):520-5
Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.
Pillois X, Gautier T, Bouillet B, Pais de Barros JP, Jeannin A, Verges B, Bonnet J, Lagrost L
J Lipid Res. 2012 Jun;53(6):1200-9
[Pheochromocytoma: rare lethal challenging diagnosis that may be encountered by gynecologists and obstetricians].
Choux C, Verges B, Isnardon JP, Rousselet JM, Douvier S, Sagot P
J Gynecol Obstet Biol Reprod (Paris). 2012 Jun;41(4):383-6
The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.
Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton AM, Grzeszczak W, Harno K, Kempler P, Satman I, Verges B
J Diabetes Sci Technol. 2012 May 1;6(3):665-73.
Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes.
Detournay B, Simon D, Guillausseau PJ, Joly D, Verges B, Attali C, Clement O, Briand Y, Delaitre O
Diabetes Metab. 2012 Apr;38(2):102-12
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.
Verges B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpere C, Moulin P, Verges-Patois B, Roussel R, Steg G, Valensi P
Arch Cardiovasc Dis. 2012 Apr;105(4):239-53.
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.
Verges B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpere C, Moulin P, Verges-Patois B, Roussel R, Steg G, Valensi P
Diabetes Metab. 2012 Apr;38(2):113-27
Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT study.
Kerlan V, Verges B, Tawil C, Lahrichi N, Doucet J
Curr Med Res Opin. 2012 Apr;28(4):503-11
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
Guiu B, Crevisy-Girod E, Binquet C, Duvillard L, Masson D, Lepage C, Hamza S, Krause D, Verges B, Minello A, Cercueil JP, Hillon P, Petit JM
Eur Radiol. 2012 Apr;22(4):855-63
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants.
Jourdan T, Demizieux L, Gresti J, Djaouti L, Gaba L, Verges B, Degrace P
Hepatology. 2012 Mar;55(3):790-9
Type 2 diabetes treatment intensification in general practice in France in 2008-2009: the DIAttitude Study.
Balkau B, Bouee S, Avignon A, Verges B, Chartier I, Amelineau E, Halimi S
Diabetes Metab. 2012 Mar;38 Suppl 3:S29-35.
Strategies for insulin initiation: insights from the French LIGHT observational study.
Verges B, Brun JM, Tawil C, Alexandre B, Kerlan V
Diabetes Metab Res Rev. 2012 Jan;28(1):97-105
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Verges B, Bonnard C, Renard E
Diabetes Metab. 2011 Dec;37(6):477-88
Significant Increase in Plasma Thyroid-Stimulating Hormone During Low-Frequency Repetitive Transcranial Magnetic Stimulation.
Trojak B, Chauvet-Gelinier JC, Verges B, Bonin B
J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):E12
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
Verges B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B
Atherosclerosis. 2011 Nov;219(1):342-8
Addressing Schemes of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A European Perspective and Expert Recommendation.
Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton A, Grzeszczak W, Harno K, Kempler P, Satman I, Verges B
Diabetes Technol Ther. 2011 Sep;13(9):959-65
Lack of an Association Between an Apolipoprotein C3 Genetic Variant and the Liver Fat Content in Patients with Type 2 Diabetes.
Petit JM, Guiu B, Masson D, Cercueil JP, Hillon P, Verges B
Hepatology. 2011 Sep 2;54(3):1109-10
Outcome in AN adult patients: A 13-year follow-up in 484 patients.
Rigaud D, Pennacchio H, Bizeul C, Reveillard V, Verges B
Diabetes Metab. 2011 Sep;37(4):305-11
Efficacy of Tube Feeding in Binge-Eating/Vomiting Patients: A 2-Month Randomized Trial With 1-Year Follow-Up.
Rigaud DJ, Brayer V, Roblot A, Brindisi MC, Verges B
JPEN J Parenter Enteral Nutr. 2011 May;35(3):356-64
Cardiovascular complications in type 1 diabetes mellitus.
Brindisi MC, Bouillet B, Verges B, Halimi S
Diabetes Metab. 2010 Nov;36(5):341-4
Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Verges B
Atherosclerosis. 2010 Aug;211(2):353-60
Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
Djaouti L, Jourdan T, Demizieux L, Chevrot M, Gresti J, Verges B, Degrace P
Diabetes Metab Res Rev. 2010 May;26(4):297-305
Abnormalities in lipoprotein kinetics in Type 2 diabetes.
Verges B
Clin Lipidol. 2010 Apr;5(2):277-89.
CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice.
Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P
Diabetes. 2010 Apr;59(4):926-34
Tube feeding at home in anorexia nervosa patients.
Rigaud D, Pennacchio H, Roblot A, Jacquet M, Tallonneau I, Verges B
Presse Med. 2009 Dec;38(12):1739-45
Liver Carbohydrate and Lipid Metabolism of Insulin-Deficient Mice Is Altered by trans-10, cis-12 Conjugated Linoleic Acid.
Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P
J Nutr. 2009 Oct;139(10):1901-7
Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.
de Barros JPP, Boualam A, Gautier T, Dumont L, Verges B, Masson D, Lagrost L
J Lipid Res. 2009 Sep;50(9):1842-51.
Thymic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: A Comparative Study on 21 Cases Among a Series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines)
Goudet P, Murat A, Cardot-Bauters C, Emy P, Baudin E, Choplin HD, Chapuis Y, Kraimps JL, Sadoul JL, Tabarin A, Verges B, Carnaille B, Niccoli-Sire P, Costa A, Calender A
World J Surg. 2009 Jun;33(6):1197-207.
Hypercholesterolaemia in anorexia nervosa: Frequency and changes during refeeding.
Rigaud D, Tallonneau I, Verges B
Diabetes Metab. 2009 Feb;35(1):57-63
Plasma N-terminal Pro-Brain Natriuretic Peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes.
Verges B, Zeller M, Beer JC, Cottin Y
Diabetes Metab. 2008 Feb;34 Suppl 1:S10-5
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Verges B
Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:15-8.
Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia.
Hansel B, Nicolle C, Lalanne F, Tondu F, Lassel T, Donazzolo Y, Ferrieres J, Krempf M, Schlienger JL, Verges B, Chapman MJ, Bruckert E
Am J Clin Nutr. 2007 Sep;86(3):790-6.
Hormonal and psychological factors linked to the increased thermic effect of food in malnourished fasting anorexia nervosa.
Rigaud D, Verges B, Colas-Linhart N, Petiet A, Moukkaddem M, Van Wymelbeke V, Brondel L
J Clin Endocrinol Metab. 2007 May;92(5):1623-9
Pathophysiology of dyslipidemia in patients with metabolic syndrome or type 2 diabetes mellitus.
Verges B
Nutr Clin Metab. 2007 Mar;21(1):9-16.
The Best of cardiac rehabilitation in 2006.
Verges B, Iliou MC, Corone S, Pierre B, Meurin P, Fischbach M, Pavy B, Carre F, Feige JM, Brion R, Douard H
Arch Mal Coeur Vaiss. 2007 Jan;100 Spec No 1:89-94.
Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Verges B
Curr Opin Lipidol. 2006 Dec;17(6):653-8.
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ, Verges B
Diabetologia. 2005 Dec;48(12):2477-81
Role for fibrate therapy in diabetes: evidence before FIELD.
Verges B
Curr Opin Lipidol. 2005 Dec;16(6):648-51.
New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.
Verges B
Diabetes Metab. 2005 Nov;31(5):429-39.
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.
Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart JC, Durlach V, Moulin P
J Clin Invest. 2005 Oct;115(10):2862-9.
Comparison of low-frequency electrical myostimulation and conventional aerobic exercise training in patients with chronic heart failure.
Deley G, Kervio G, Verges B, Hannequin A, Petitdant MF, Salmi-Belmihoub S, Grassi B, Casillas JM
Eur J Cardiovasc Prev Rehabil. 2005 Jun;12(3):226-33.
Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction.
Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, Beer JC, Oudot A, Rioufol G, Makki H, Farnier M, Rochette L, Verges B, Cottin Y
Arch Intern Med. 2005 May 23;165(10):1192-8.
Diabetic dyslipidaemia: insights for optimizing patient management.
Verges B
Curr Med Res Opin. 2005;21 Suppl 1:S29-40.